Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
Oki S, Sone K, Oda K, Hamamoto R, Ikemura M, Maeda D, Takeuchi M, Tanikawa M, Mori-Uchino M, Nagasaka K, Miyasaka A, Kashiyama T, Ikeda Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Fukayama M, Osuga Y, Fujii T. Oki S, et al. Among authors: miyasaka a. Oncotarget. 2017 Jun 20;8(25):40402-40411. doi: 10.18632/oncotarget.16316. Oncotarget. 2017. PMID: 28418882 Free PMC article.
The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition.
Fukuda T, Oda K, Wada-Hiraike O, Sone K, Inaba K, Ikeda Y, Miyasaka A, Kashiyama T, Tanikawa M, Arimoto T, Kuramoto H, Yano T, Kawana K, Osuga Y, Fujii T. Fukuda T, et al. Among authors: miyasaka a. Gynecol Oncol. 2015 Jun;137(3):538-45. doi: 10.1016/j.ygyno.2015.03.053. Epub 2015 Apr 1. Gynecol Oncol. 2015. PMID: 25842161
Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.
Ikeda Y, Oda K, Ishihara H, Wada-Hiraike O, Miyasaka A, Kashiyama T, Inaba K, Fukuda T, Sone K, Matsumoto Y, Arimoto T, Maeda D, Ikemura M, Fukayama M, Kawana K, Yano T, Aoki D, Osuga Y, Fujii T. Ikeda Y, et al. Among authors: miyasaka a. Br J Cancer. 2015 Nov 17;113(10):1477-83. doi: 10.1038/bjc.2015.369. Epub 2015 Nov 10. Br J Cancer. 2015. PMID: 26554657 Free PMC article.
Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer.
Chuwa AH, Sone K, Oda K, Ikeda Y, Fukuda T, Wada-Hiraike O, Inaba K, Makii C, Takeuchi M, Oki S, Miyasaka A, Kashiyama T, Arimoto T, Kuramoto H, Kawana K, Yano T, Osuga Y, Fujii T. Chuwa AH, et al. Among authors: miyasaka a. Gynecol Oncol. 2016 Jun;141(3):564-569. doi: 10.1016/j.ygyno.2016.04.003. Epub 2016 Apr 16. Gynecol Oncol. 2016. PMID: 27079211
Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.
Inaba K, Oda K, Aoki K, Sone K, Ikeda Y, Miyasaka A, Kashiyama T, Fukuda T, Makii C, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T. Inaba K, et al. Among authors: miyasaka a. Oncotarget. 2016 May 17;7(20):29577-91. doi: 10.18632/oncotarget.8807. Oncotarget. 2016. PMID: 27102436 Free PMC article.
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T. Kukita A, et al. Among authors: miyasaka a. Biochem Biophys Res Commun. 2019 May 28;513(2):340-346. doi: 10.1016/j.bbrc.2019.03.155. Epub 2019 Apr 4. Biochem Biophys Res Commun. 2019. PMID: 30955858
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y. Shoji K, et al. Among authors: miyasaka a. PLoS One. 2012;7(5):e37431. doi: 10.1371/journal.pone.0037431. Epub 2012 May 25. PLoS One. 2012. PMID: 22662154 Free PMC article.
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Kashiyama T, Oda K, Ikeda Y, Shiose Y, Hirota Y, Inaba K, Makii C, Kurikawa R, Miyasaka A, Koso T, Fukuda T, Tanikawa M, Shoji K, Sone K, Arimoto T, Wada-Hiraike O, Kawana K, Nakagawa S, Matsuda K, McCormick F, Aburatani H, Yano T, Osuga Y, Fujii T. Kashiyama T, et al. Among authors: miyasaka a. PLoS One. 2014 Feb 4;9(2):e87220. doi: 10.1371/journal.pone.0087220. eCollection 2014. PLoS One. 2014. PMID: 24504419 Free PMC article.
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Miyasaka A, Oda K, Ikeda Y, Wada-Hiraike O, Kashiyama T, Enomoto A, Hosoya N, Koso T, Fukuda T, Inaba K, Sone K, Uehara Y, Kurikawa R, Nagasaka K, Matsumoto Y, Arimoto T, Nakagawa S, Kuramoto H, Miyagawa K, Yano T, Kawana K, Osuga Y, Fujii T. Miyasaka A, et al. BMC Cancer. 2014 Mar 13;14:179. doi: 10.1186/1471-2407-14-179. BMC Cancer. 2014. PMID: 24625059 Free PMC article.
93 results